Identification and quantification of dopamine receptor 2 in human eutopic and ectopic endometrium: a novel molecular target for endometriosis therapy

Novella-Maestre E, Edurne Novella-Maestre, Carmen Cardá, Carmen Carda, Carda C, Ruiz-Sauri A, Amparo Ruiz‐Saurí, Amparo Ruiz-Sauri, Juan A Garcia-Velasco, Juan A. García-Velasco, Carlos Simon, Carlos Simón, António Pellicer, Antonio Pellicer
Biology of reproduction · 2010 · vol. 83(5) , pp. 866–873 · doi:10.1095/biolreprod.110.084392 · PMID:20574053 · W2116209432
Other OA: hybrid CC0 ⤵ 54 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

Dopamine receptor 2 (DRD2) is present in human eutopic and ectopic endometrium, with its expression modulated by cabergoline and correlated with VEGF and KDR levels, suggesting a potential therapeutic target for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Previous studies in an experimental mouse model of endometriosis have shown that the dopamine agonist (DA) cabergoline (Cb2) reduces angiogenesis and endometriotic lesions, hypothetically binding to the dopamine receptor type-2 (DRD2). To date, this has not been described in human endometrium and/or endometriotic lesions. Thus, we aimed to investigate the presence of DRD2 in said tissues. Endometrium fragments were implanted in nude mice treated with different doses of Cb2. Polymerase chain reaction assays and immunohistochemistry were performed to analyze the gene and protein expressions (respectively) of DRD2, VEGF, and VEGF receptor-2 (KDR). In addition, lesions and endometrium from women with mild and severe endometriosis and endometrium from healthy women were collected to analyze their gene expression profile. In experimental endometriosis, DRD2 was expressed at gene and protein levels in all three groups. VEGF gene and protein expressions were significantly lower in lesions treated with Cb2 than in controls. KDR protein expression was significantly lower in experimental lesions treated with Cb2 than in controls. In eutopic endometria, there was a significant decrease in DRD2 expression and an increase in VEGF in women with mild and severe endometriosis with respect to healthy patients. In endometriosis, KDR expression was significantly higher in red than in white and black lesions. VEGF expression was significantly lower in black than in red lesions. DRD2 is present in the human eutopic and ectopic endometrium and is regulated by DA, which provides the rationale for pilot studies to explore its use in the treatment of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Dopamine Agonists Endometriosis Endometrium Ergolines Receptors, Dopamine D2 Adolescent Adolescent Adult Adult Animals Animals Cabergoline Cabergoline Dopamine Agonists Dopamine Agonists Dose-Response Relationship, Drug Dose-Response Relationship, Drug Endometriosis Endometriosis Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (42)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-24T06:12:55.650802+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:07:39.929932+00:00
License: CC0 · commercial use OK